IMMP – Immutep Limited ADR
Immutep LimitedIMMP
$3.87Name : Immutep Limited
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $28,516,508.00
EPSttm : -7.3
Immutep Limited
$3.87
7.50%$0.27
IMMP — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
0.45
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
4.29
EPS This/Next Y
-0.11
Price
3.58
Target Price
19.66
Analyst Recom
1.75
Performance Q
-55.39
Upside
-4,548.9%
Beta
2.28
Ticker: IMMP
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | IMMP | 3.53 | 0.03 | 999.99 | 3584 |
| 2026-10-14 | IMMP | 3.405 | N/A | N/A | 0 |
| 2026-10-15 | IMMP | 3.19 | N/A | N/A | 0 |
| 2026-10-16 | IMMP | 3.19 | 0.01 | 999.99 | 3511 |
| 2026-10-19 | IMMP | 3.185 | 0.01 | 999.99 | 3511 |
| 2026-10-20 | IMMP | 3.18 | 0.01 | 999.99 | 3511 |
| 2026-10-21 | IMMP | 3.255 | 0.01 | 999.99 | 3511 |
| 2026-10-22 | IMMP | 3.21 | 0.01 | 999.99 | 3511 |
| 2026-10-23 | IMMP | 3.2 | 0.01 | 999.99 | 3511 |
| 2026-10-26 | IMMP | 3.09 | N/A | N/A | 0 |
| 2026-10-27 | IMMP | 3.13 | N/A | N/A | 0 |
| 2026-10-28 | IMMP | 3.35 | N/A | N/A | 0 |
| 2026-10-29 | IMMP | 3.35 | N/A | N/A | 0 |
| 2026-10-30 | IMMP | 3.09 | N/A | N/A | 0 |
| 2026-11-02 | IMMP | 3.05 | N/A | N/A | 0 |
| 2026-11-03 | IMMP | 2.99 | N/A | N/A | 0 |
| 2026-11-04 | IMMP | 2.94 | N/A | N/A | 0 |
| 2026-11-05 | IMMP | 2.8 | N/A | N/A | 0 |
| 2026-11-06 | IMMP | 3.49 | N/A | N/A | 0 |
| 2026-11-09 | IMMP | 3.77 | N/A | N/A | 0 |
| 2026-11-10 | IMMP | 3.49 | N/A | N/A | 0 |
| 2026-11-11 | IMMP | 3.59 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | IMMP | 3.49 | - | - | -4.00 |
| 2026-10-14 | IMMP | 3.36 | - | - | -4.00 |
| 2026-10-15 | IMMP | 3.19 | - | - | -4.00 |
| 2026-10-16 | IMMP | 3.19 | - | - | -4.00 |
| 2026-10-19 | IMMP | 3.16 | - | - | -4.00 |
| 2026-10-20 | IMMP | 3.16 | - | - | -4.00 |
| 2026-10-21 | IMMP | 3.23 | - | - | -4.00 |
| 2026-10-22 | IMMP | 3.20 | - | - | -4.00 |
| 2026-10-23 | IMMP | 3.17 | - | - | -4.00 |
| 2026-10-26 | IMMP | 3.10 | - | - | -3.12 |
| 2026-10-27 | IMMP | 3.14 | - | - | -3.12 |
| 2026-10-28 | IMMP | 3.31 | - | - | -3.12 |
| 2026-10-29 | IMMP | 3.34 | - | - | -3.12 |
| 2026-10-30 | IMMP | 3.09 | - | - | -3.12 |
| 2026-11-02 | IMMP | 2.99 | - | - | -3.12 |
| 2026-11-03 | IMMP | 2.97 | - | - | -3.12 |
| 2026-11-04 | IMMP | 2.90 | - | - | -3.12 |
| 2026-11-05 | IMMP | 2.70 | - | - | -3.12 |
| 2026-11-06 | IMMP | 3.26 | - | - | -3.12 |
| 2026-11-09 | IMMP | 3.71 | - | - | -3.12 |
| 2026-11-10 | IMMP | 3.52 | - | - | -3.12 |
| 2026-11-11 | IMMP | 3.58 | - | - | -3.12 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | IMMP | 0.00 | 0 | 0.64 |
| 2026-10-14 | IMMP | 0.00 | 0 | 0.64 |
| 2026-10-15 | IMMP | 0.00 | 0 | 0.64 |
| 2026-10-16 | IMMP | 0.00 | 0 | 0.64 |
| 2026-10-19 | IMMP | 0.00 | 0 | 0.64 |
| 2026-10-20 | IMMP | 0.00 | 0 | 0.64 |
| 2026-10-21 | IMMP | 0.00 | 0 | 0.64 |
| 2026-10-22 | IMMP | 0.00 | 0 | 0.64 |
| 2026-10-23 | IMMP | 0.00 | 0 | 0.64 |
| 2026-10-26 | IMMP | 0.00 | 0 | 0.64 |
| 2026-10-27 | IMMP | 0.00 | 0 | 0.46 |
| 2026-10-28 | IMMP | 0.00 | 0 | 0.46 |
| 2026-10-29 | IMMP | 0.00 | 0 | 0.46 |
| 2026-10-30 | IMMP | 0.00 | 0 | 0.46 |
| 2026-11-02 | IMMP | 0.00 | -96.53 | 0.46 |
| 2026-11-03 | IMMP | 0.00 | -96.53 | 0.46 |
| 2026-11-05 | IMMP | 0.00 | -96.53 | 0.46 |
| 2026-11-06 | IMMP | 0.00 | -96.53 | 0.46 |
| 2026-11-09 | IMMP | 0.00 | -95.77 | 0.46 |
| 2026-11-10 | IMMP | 0.00 | -95.77 | 0.46 |
| 2026-11-11 | IMMP | 0.00 | -95.77 | 0.45 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
-95.77
Beta
2.28
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
29
Growth Score
16
Sentiment Score
48
Actual DrawDown %
95.9
Max Drawdown 5-Year %
-96.9
Target Price
19.66
P/E
Forward P/E
PEG
P/S
2.65
P/B
0.62
P/Free Cash Flow
EPS
-7.28
Average EPS Est. Cur. Y
-3.12
EPS Next Y. (Est.)
-3.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-534.13
Relative Volume
2.97
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
0.9
EPS 1 30Days Diff
0.88
EBIT Estimation
◆
IMMP
Healthcare
$3.60
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
49
Range 1M
74.2%
Sup Dist
7.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
75.4%
EPS NY
14.3%
52W%
1.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+446.1% upside
Upside
+446.1%
Quality
29
IMMP — P/E HistoricalBiotechnology
Immutep LimitedSector: Healthcare
Industry: Biotechnology
Employees:
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
IMMP
Latest News
—
Caricamento notizie per IMMP…
stock quote shares IMMP – Immutep Limited ADR Stock Price stock today
news today IMMP – Immutep Limited ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMMP – Immutep Limited ADR yahoo finance google finance
stock history IMMP – Immutep Limited ADR invest stock market
stock prices IMMP premarket after hours
ticker IMMP fair value insiders trading